Association of P53 and Mdm2 in the Development and Progression of Non-small Cell Lung Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Feb 13

PMID 25672611

Citations 7

Authors

Jamsheed Javid

Rashid Mir

P K Julka

P C Ray

Alpana Saxena

Affiliations

Soon will be listed here.

Abstract

MDM2 protein is an important regulator of the p53 pathway and has a large effect on the anti-tumorigenic activity of the p53. Presently, we aimed to analyze the possible association of p53 and mdm2 in the development and progression of non-small cell lung cancer. In addition, impact of an important gene promoter polymorphism of MDM2 (T309G, rs 2279744) on its gene expression and ultimately of the TP53 was investigated in non-small cell lung cancer patients. A case-control study using peripheral blood samples of 100 non-small cell lung cancer patients and 100 cancer free healthy controls was conducted. Expression profile of MDM2 and TP53 gene were evaluated by using quantitative real time polymerase chain reaction assay, and MDM2 promoter polymorphism were analyzed by amplification refractory mutation system polymerase chain reaction. Non-small cell lung cancer patients expressed more than 6-fold increased mdm2 and about 7-folds decreased in p53 expression levels compared to healthy controls. Higher fold change increase of mdm2 and/or decrease of p53 were associated with advanced status and poor clinical outcome of the patients. A significant increase in mdm2 of about 14-folds and decrease in p53 of about 16.5-fold were observed among patients with MDM2 (309GG) genotype vs just 2.2-fold increase in mdm2 and 1.9-fold decrease in p53 among patients with MDM2 (309TT) genotype. In conclusion, present study demonstrated that MDM2 (309 T > G) polymorphism may be one of the important factors for the increased expression mdm2, which was associated with down-regulation of p53 at messenger RNA (mRNA) level and ultimately may contribute in the poor clinical outcome of the non-small cell lung cancer patients, thus may prove as a promising target for the treatment of non-small cell lung cancer at molecular level.

Citing Articles

Circulating miR-206 and miR-1246 as Markers in the Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease.

Cordoba-Lanus E, Dominguez de-Barros A, Oliva A, Mayato D, Gonzalvo F, Remirez-Sanz A Int J Mol Sci. 2023; 24(15).

PMID: 37569812 PMC: 10418760. DOI: 10.3390/ijms241512437.

Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information.

Parvin S, Sedighian H, Sohrabi E, Mahboobi M, Rezaei M, Ghasemi D Biochem Genet. 2021; 60(4):1253-1273.

PMID: 34855070 DOI: 10.1007/s10528-021-10163-7.

DriveWays: a method for identifying possibly overlapping driver pathways in cancer.

Baali I, Erten C, Kazan H Sci Rep. 2020; 10(1):21971.

PMID: 33319839 PMC: 7738685. DOI: 10.1038/s41598-020-78852-8.

Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns.

Dong Y, Qin L, Tong Y, He Q, Wang L, Song K PeerJ. 2020; 8:e8349.

PMID: 32030321 PMC: 6995662. DOI: 10.7717/peerj.8349.

Individual and combined effect of and gene polymorphisms in lung cancer.

Stumbryte A, Gudleviciene Z, Kundrotas G, Dabkeviciene D, Kunickaite A, Cicenas S Oncotarget. 2018; 9(3):3214-3229.

PMID: 29423041 PMC: 5790458. DOI: 10.18632/oncotarget.22756.

References

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y . MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007; 13(14):4123-9. DOI: 10.1158/1078-0432.CCR-07-0609. View

Aikawa H, Sato M, Fujimura S, Takahashi H, Endo C, Sakurada A . MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med. 2000; 5(6):631-3. DOI: 10.3892/ijmm.5.6.631. View

Olsson H, Hultman P, Rosell J, Soderkvist P, Jahnson S . MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 2013; 13:5. PMC: 3574032. DOI: 10.1186/1471-2490-13-5. View

Weglarz L, Molin I, Orchel A, Parfiniewicz B, Dzierzewicz Z . Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate. Acta Biochim Pol. 2006; 53(2):349-56. View

Nathanson S, Linden M, Tender P, Zarbo R, Jacobsen G, Nelson L . Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum. 1994; 37(6):527-34. DOI: 10.1007/BF02050985. View

Thut C, Goodrich J, Tjian R . Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997; 11(15):1974-86. PMC: 316412. DOI: 10.1101/gad.11.15.1974. View

Gorgoulis V, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M . Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol. 1998; 153(6):1749-65. PMC: 2233978. DOI: 10.1016/S0002-9440(10)65690-8. View

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

Lee J, Yoon A, Kalapurakal S, Ro J, Lee J, Tu N . Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995; 13(8):1893-903. DOI: 10.1200/JCO.1995.13.8.1893. View

10.

Ahnen D, Feigl P, Quan G, Lovato L, Bunn Jr P, Stemmerman G . Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998; 58(6):1149-58. View

11.

Malik P, Sharma M, Mohanti B, Shukla N, Deo S, Mohan A . Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev. 2013; 14(1):489-94. DOI: 10.7314/apjcp.2013.14.1.489. View

12.

Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Rassidakis A, Spandidos D . A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996; 180(2):129-37. DOI: 10.1002/(SICI)1096-9896(199610)180:2<129::AID-PATH646>3.0.CO;2-8. View

13.

Anant M, Guleria R, Pathak A, Bhutani M, Pal H, Charu M . Quality of life measures in lung cancer. Indian J Cancer. 2005; 42(3):125-32. DOI: 10.4103/0019-509x.17056. View

14.

Rayburn E, Zhang R, He J, Wang H . MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005; 5(1):27-41. DOI: 10.2174/1568009053332636. View

15.

Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M . MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer. 2004; 43(3):285-95. DOI: 10.1016/j.lungcan.2003.09.010. View

16.

Wadgaonkar R, Collins T . Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J Biol Chem. 1999; 274(20):13760-7. DOI: 10.1074/jbc.274.20.13760. View

17.

Shi D, Gu W . Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity. Genes Cancer. 2012; 3(3-4):240-8. PMC: 3494363. DOI: 10.1177/1947601912455199. View

18.

Xiao M, Zhang L, Zhu X, Huang J, Jiang H, Hu S . Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer. 2010; 10:147. PMC: 2861659. DOI: 10.1186/1471-2407-10-147. View

19.

Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T . Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2005; 27(1):110-7. DOI: 10.1002/humu.20277. View

20.

Terry K, McGrath M, Lee I, Buring J, De Vivo I . MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):983-6. PMC: 2728574. DOI: 10.1158/1055-9965.EPI-07-2872. View